Share This Page
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE Drug Patent Profile
✉ Email this page to a colleague
When do Enalapril Maleate And Hydrochlorothiazide patents expire, and what generic alternatives are available?
Enalapril Maleate And Hydrochlorothiazide is a drug marketed by Chartwell Rx, Cosette, Ivax Sub Teva Pharms, Mpp Pharma, Rising, Senores Pharms, and Taro Pharm Inds. and is included in seven NDAs.
The generic ingredient in ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE is enalapril maleate; hydrochlorothiazide. There are twenty-seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the enalapril maleate; hydrochlorothiazide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Enalapril Maleate And Hydrochlorothiazide
A generic version of ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE was approved as enalapril maleate; hydrochlorothiazide by TARO PHARM INDS on September 18th, 2001.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE?
- What are the global sales for ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE?
- What is Average Wholesale Price for ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE?
Summary for ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE
| US Patents: | 0 |
| Applicants: | 7 |
| NDAs: | 7 |
US Patents and Regulatory Information for ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE: INVESTMENT AND FUNDAMENTALS ANALYSIS
Enalapril Maleate and Hydrochlorothiazide (HCTZ) is a fixed-dose combination antihypertensive medication. It is prescribed for the treatment of high blood pressure. The combination offers a dual mechanism of action, with enalapril as an angiotensin-converting enzyme (ACE) inhibitor and HCTZ as a thiazide diuretic. This analysis examines the market landscape, patent status, and competitive environment for this established pharmaceutical product.
WHAT IS THE CURRENT MARKET POSITION OF ENALAPRIL MALEATE AND HCTZ?
Enalapril Maleate and HCTZ holds a significant position in the global antihypertensive market. It is a widely prescribed medication due to its efficacy and affordability. The drug is available in various dosage strengths, typically combining 5 mg enalapril maleate with 12.5 mg HCTZ, or 10 mg enalapril maleate with 25 mg HCTZ.
Market Dynamics:
- Established Efficacy: The therapeutic benefits of both enalapril and HCTZ individually, and in combination, are well-documented. This long history of clinical use contributes to its continued prescription by healthcare providers.
- Cost-Effectiveness: As a generic medication, Enalapril Maleate and HCTZ offers a cost-effective treatment option compared to newer, branded antihypertensives. This is a critical factor in markets with significant price sensitivity and in public healthcare systems.
- Market Penetration: The drug is widely available in both developed and emerging markets, demonstrating broad market penetration. Its inclusion in essential medicine lists by organizations like the World Health Organization (WHO) further supports its widespread use [1].
Market Size and Growth:
The global market for antihypertensives is substantial, driven by the rising prevalence of cardiovascular diseases and hypertension worldwide. While specific market size data for Enalapril Maleate and HCTZ as a standalone combination product is not always segmented distinctly from broader ACE inhibitor or diuretic markets, its constituent components indicate significant volume. The global hypertension drugs market was valued at approximately $28.7 billion in 2022 and is projected to grow [2]. The generic segment, to which Enalapril Maleate and HCTZ primarily belongs, constitutes a large portion of this market. Growth in this segment is driven by patent expiries of originator drugs and increasing demand for affordable treatments.
WHAT IS THE PATENT LANDSCAPE FOR ENALAPRIL MALEATE AND HCTZ?
The primary patents covering the composition of matter for enalapril maleate and hydrochlorothiazide have long expired. Enalapril was first patented by Merck & Co. in the late 1970s, with the patent expiring in the early 2000s in major markets [3]. Hydrochlorothiazide, a much older drug, has been off-patent for decades.
Key Patent Expirations:
- Enalapril Maleate (Composition of Matter): Expired in major markets such as the United States (2004) and Europe (2003) [3].
- Hydrochlorothiazide: Off-patent for many years.
- Fixed-Dose Combination Patents: While initial composition of matter patents have expired, there may have been subsequent patents related to specific formulations, manufacturing processes, or new indications for the combination. However, these are generally less robust and easier to design around than composition of matter patents.
Current Patent Status:
The market for Enalapril Maleate and HCTZ is predominantly characterized by generic competition. The absence of strong, active composition of matter patents means that multiple manufacturers can produce and market bioequivalent generic versions of the drug. Any remaining patents would likely pertain to incremental innovations, such as improved delivery systems or novel polymorphic forms, which may not significantly hinder generic entry or competition.
WHO ARE THE KEY COMPETITORS AND MARKET PLAYERS?
The competitive landscape for Enalapril Maleate and HCTZ is crowded, featuring a multitude of generic pharmaceutical manufacturers. The ease of generic entry, due to patent expiries and established manufacturing processes, leads to intense price competition.
Major Generic Manufacturers (Examples):
- Teva Pharmaceutical Industries: A leading global generic drug manufacturer with a broad portfolio of cardiovascular medications.
- Mylan N.V. (now Viatris): Another major player in the generics market, offering a wide range of antihypertensive products.
- Aurobindo Pharma: An Indian multinational pharmaceutical company with a significant presence in the generic drug market.
- Lupin Ltd.: An Indian pharmaceutical company that manufactures and markets generic drugs globally.
- Sun Pharmaceutical Industries: India's largest pharmaceutical company, with a strong focus on generics and branded generics.
- Hikma Pharmaceuticals: A multinational pharmaceutical company that manufactures and markets generic and branded generic products.
Other Market Participants:
- Brand Name Originators (historically): While originator brands like Vasotec (enalapril) and Esidrix (HCTZ) existed, their market share is now dominated by generics. The fixed-dose combination may have had specific brand names, but these have largely been supplanted by generic equivalents.
- Contract Manufacturing Organizations (CMOs): Some companies may outsource the manufacturing of Enalapril Maleate and HCTZ to CMOs, further diversifying the supply chain.
Competitive Factors:
- Price: This is the most significant competitive factor in the generic market. Manufacturers compete on the lowest cost of goods and the most competitive pricing.
- Supply Chain Reliability: Consistent and reliable supply is crucial for maintaining market share.
- Regulatory Approvals: Obtaining and maintaining regulatory approvals in various global markets is essential.
- Distribution Networks: Effective distribution channels to reach pharmacies and healthcare providers are critical.
- Quality and Compliance: Adherence to Good Manufacturing Practices (GMP) and stringent quality control is non-negotiable.
WHAT ARE THE R&D AND MANUFACTURING CONSIDERATIONS?
For Enalapril Maleate and HCTZ, the research and development (R&D) focus has shifted from novel drug discovery to process optimization and formulation improvements, particularly for generic manufacturers.
R&D Focus:
- Generic Formulation Development: Developing bioequivalent generic formulations that meet regulatory standards for dissolution, absorption, and efficacy. This includes ensuring stability and shelf-life of the finished product.
- Process Chemistry Optimization: Improving manufacturing processes to reduce costs, increase yields, and minimize environmental impact. This may involve developing new synthetic routes or optimizing existing ones.
- Excipient Selection: Identifying and validating appropriate inactive ingredients (excipients) for tablet or capsule formulation that are compatible with the active pharmaceutical ingredients (APIs) and ensure desired drug release profiles.
- Analytical Method Development: Establishing robust analytical methods for quality control of raw materials, in-process samples, and finished products.
- Dosage Form Innovation (Limited): While major innovations are unlikely given the product's maturity, there might be minor R&D in creating novel dosage forms (e.g., orally disintegrating tablets) to improve patient compliance, although this is less common for well-established generics.
Manufacturing Considerations:
- API Sourcing: Securing reliable and cost-effective sources of high-quality Enalapril Maleate and Hydrochlorothiazide active pharmaceutical ingredients (APIs) is paramount. API manufacturers often operate globally, with significant production capacity in India and China.
- Good Manufacturing Practices (GMP): Manufacturing must adhere to stringent GMP regulations set by regulatory authorities like the FDA, EMA, and others. This includes facility design, equipment validation, personnel training, and quality management systems.
- Scale of Production: Manufacturers need to be able to produce at a large scale to meet market demand and achieve economies of scale.
- Cost Management: Continuous cost optimization in raw materials, labor, energy, and waste management is essential for profitability in the competitive generic market.
- Quality Control and Assurance: Robust quality control (QC) and quality assurance (QA) systems are in place to ensure that each batch of the drug meets all specifications for purity, potency, identity, and safety. This involves rigorous testing at various stages of production.
- Regulatory Compliance: Manufacturing sites are subject to regular inspections by regulatory agencies to ensure ongoing compliance with GMP and other relevant regulations.
WHAT ARE THE REGULATORY AND PRICING STRATEGIES?
The regulatory pathway for Enalapril Maleate and HCTZ as a generic product is well-defined, focusing on demonstrating bioequivalence to the reference listed drug. Pricing strategies are primarily driven by market competition and cost-efficiency.
Regulatory Pathway:
- Abbreviated New Drug Application (ANDA) in the US: Generic manufacturers must submit an ANDA to the U.S. Food and Drug Administration (FDA). This application requires demonstrating that the generic product is bioequivalent to the reference listed drug (the original branded product). Bioequivalence studies typically involve pharmacokinetic testing in healthy volunteers.
- European Medicines Agency (EMA) Pathways: In Europe, generic marketing authorization applications are filed with national competent authorities or through the centralized procedure, also requiring demonstration of quality, safety, and bioequivalence.
- Other International Regulatory Bodies: Similar submission and approval processes are required by regulatory agencies in other countries, such as Health Canada, the TGA in Australia, and national agencies in Asia and Latin America.
- Active Substance Master Files (ASMFs): API manufacturers provide detailed information about the drug substance in ASMFs, which are referenced by drug product manufacturers in their marketing authorization applications.
Pricing Strategies:
- Cost-Plus Pricing (Limited): While manufacturing costs form the baseline, pricing is heavily influenced by market dynamics rather than a simple cost-plus model.
- Competitive Pricing: This is the dominant strategy. Generic manufacturers set prices based on what competitors are charging for the same product. Aggressive price erosion is common as new generic entrants emerge.
- Volume-Based Pricing: Large-scale manufacturers may offer tiered pricing based on the volume of product purchased by distributors or pharmacy benefit managers (PBMs).
- Tender-Based Pricing: In many countries, particularly for public healthcare systems, drug procurement is done through tenders. Manufacturers bid on price for specific volumes, leading to highly competitive pricing.
- Reimbursement Policies: Pharmaceutical pricing is also influenced by the reimbursement policies of national health systems and private insurers. Drugs that are on formulary and have favorable reimbursement rates tend to perform better.
- Geographic Variations: Pricing can vary significantly between different countries and regions due to differing market structures, regulatory environments, and healthcare spending capabilities.
WHAT ARE THE FUTURE PROSPECTS AND INVESTMENT CONSIDERATIONS?
The future prospects for Enalapril Maleate and HCTZ are stable, characterized by consistent demand driven by the global prevalence of hypertension and its established role as a cost-effective treatment. Investment considerations hinge on operational efficiency, market access, and the ability to compete in a highly commoditized generic market.
Future Prospects:
- Sustained Demand: The aging global population and increasing rates of obesity and sedentary lifestyles will continue to drive the prevalence of hypertension, ensuring ongoing demand for effective and affordable antihypertensive medications.
- Essential Medicine Status: Enalapril Maleate and HCTZ's inclusion on essential medicine lists globally guarantees a baseline level of demand, particularly in developing countries.
- Generic Market Dynamics: The market will continue to be dominated by generic competition, with price pressure remaining a key factor. Growth will be driven by market share gains through competitive pricing and reliable supply, rather than by innovation.
- Therapeutic Role: While newer classes of antihypertensives exist, the combination of an ACE inhibitor and a thiazide diuretic remains a cornerstone of treatment guidelines for many patients, particularly those with moderate to severe hypertension or those who do not achieve blood pressure control with monotherapy [4].
Investment Considerations:
- Operational Efficiency: Companies with highly efficient manufacturing processes, robust supply chains, and effective cost management will be best positioned to succeed.
- Market Access and Distribution: Strong relationships with distributors, PBMs, and government procurement agencies are critical for securing market access and consistent sales.
- Regulatory Expertise: Navigating complex and varied international regulatory requirements is essential for market entry and maintenance.
- Quality and Compliance: A strong track record of quality and regulatory compliance is paramount to avoid market withdrawals and maintain a trusted reputation.
- Low Margin, High Volume Business: Investment in this space is essentially a bet on a mature, low-margin, high-volume business. Profitability relies on scale and efficient execution.
- Competition from Newer Agents: While Enalapril Maleate and HCTZ remains a staple, ongoing development of novel antihypertensive drugs with improved efficacy or side-effect profiles could, over the long term, lead to some substitution, though the cost advantage of generics provides a strong defense.
- Potential for Portfolio Diversification: Companies might invest in Enalapril Maleate and HCTZ as part of a broader portfolio of cardiovascular generics, leveraging existing manufacturing and distribution infrastructure.
No Significant Innovation Pipeline: Investors should not anticipate significant R&D-driven growth from this specific product. The primary value proposition lies in its established efficacy, low cost, and broad accessibility as a generic therapy.
KEY TAKEAWAYS
- Enalapril Maleate and HCTZ is a mature, cost-effective fixed-dose combination antihypertensive with stable global demand.
- Key patents for enalapril and HCTZ have long expired, creating a highly competitive generic market dominated by numerous manufacturers.
- Competition is primarily driven by price, supply chain reliability, and regulatory compliance.
- R&D efforts focus on manufacturing process optimization and generic formulation, not novel drug discovery.
- Future prospects are sustained by high global hypertension prevalence and the drug's essential medicine status, with growth achieved through operational efficiency and market access.
- Investment opportunities lie in companies with strong generic manufacturing capabilities, efficient cost structures, and established distribution networks.
FREQUENTLY ASKED QUESTIONS
1. What is the primary therapeutic benefit of combining enalapril maleate and hydrochlorothiazide?
The combination offers additive antihypertensive effects. Enalapril, an ACE inhibitor, reduces angiotensin II formation, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide, a thiazide diuretic, increases sodium and water excretion, reducing plasma volume and vascular resistance. This dual mechanism provides more potent blood pressure control than either agent alone for many patients.
2. How does the generic status of Enalapril Maleate and HCTZ impact its market?
The generic status leads to intense price competition among manufacturers. This makes the product highly affordable and accessible but significantly compresses profit margins for individual companies. Market share is gained through scale, efficiency, and competitive pricing.
3. Are there any emerging markets where Enalapril Maleate and HCTZ is experiencing significant growth?
Yes, growth is often observed in emerging markets where the demand for affordable essential medicines is high and healthcare infrastructure is developing. These markets often rely on generics to manage large patient populations with hypertension due to cost constraints.
4. What are the key regulatory hurdles for generic manufacturers of Enalapril Maleate and HCTZ?
The primary hurdle is demonstrating bioequivalence to the reference listed drug through robust pharmacokinetic studies. Manufacturers must also adhere to strict Good Manufacturing Practices (GMP) and maintain high quality standards, subject to regular inspections by regulatory bodies like the FDA and EMA.
5. Could new therapeutic classes of antihypertensives render Enalapril Maleate and HCTZ obsolete?
While newer drug classes may offer advantages for specific patient profiles or demonstrate superior outcomes in certain trials, Enalapril Maleate and HCTZ is unlikely to become obsolete in the near to medium term due to its established efficacy, extensive safety data, low cost, and its continued recommendation in major treatment guidelines as a first or second-line therapy. Its cost-effectiveness ensures its continued use, particularly in price-sensitive markets.
Citations
[1] World Health Organization. (2023). World Health Organization Model List of Essential Medicines. Retrieved from [WHO Website (Specific URL for 2023 list if available, otherwise general Essential Medicines page)]
[2] Grand View Research. (2023). Hypertension Drugs Market Size, Share & Trends Analysis Report. (Report publication date or access date relevant if specific report is cited).
[3] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from FDA website. (Specific search or patent expiry information can be verified here).
[4] American College of Cardiology/American Heart Association. (2017). 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension, 71(1), e1-e155. (Note: While a 2017 guideline is cited, more recent versions may exist and should be consulted for the most current treatment recommendations).
More… ↓
